Lifevantage Corp Stock Price, News & Analysis

LifeVantage Corporation (LFVN) reported its second fiscal quarter results for 2023, revealing a revenue increase of 2.8% to $53.7 million. When adjusted for foreign currency fluctuations, revenue rose approximately 7.4%. The Americas saw a 14.4% revenue increase, while Asia/Pacific & Europe faced a 20.2% decline. The company reported a net loss of $1.1 million or $0.08 per diluted share, contrasting with a net income of $0.1 million from the previous year. Adjusted EBITDA was $0.8 million. Despite the challenges, the company maintains a strong balance sheet with $17.4 million in cash and no debt. Guidance for the fiscal year suggests revenues between $202 million and $212 million.

LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the second quarter ended December 31, 2022, on February 2, 2023, after the market closes. The company will host a conference call for investors at 2:30 p.m. MT (4:30 p.m. ET). Interested parties can call (877) 704-4453 in the U.S. or (201) 389-0920 internationally to participate. A replay will be available until February 9, 2023. Additionally, a live webcast will be accessible on the company’s Investor Relations website and archived for 30 days.

LifeVantage Corporation (Nasdaq: LFVN) announced its strategic transformation initiative, LV360, aimed at enhancing the Consultant and Customer experience. Key features include the launch of Evolve, a new compensation model, and the Rewards Circle customer loyalty program, set to debut on March 1, 2023. Over 10,000 Consultants participated in the announcement via a global broadcast. The initiative aims to strengthen market position and address evolving consumer trends with new products, enhanced e-commerce, and extensive training sessions scheduled globally. The company's focus remains on solidifying its reputation in health and wellness.

LifeVantage Corporation (Nasdaq: LFVN) has declared a quarterly cash dividend of $0.03 per share, to be distributed on December 15, 2022, to shareholders on record as of December 1, 2022. This announcement reflects the company's commitment to providing returns to its investors amidst its focus on nutrigenomics and health solutions. LifeVantage markets a range of dietary supplements, including its flagship product Protandim^®, and is dedicated to research and development in natural health advancements.

LifeVantage Corporation (Nasdaq: LFVN) reported Q1 fiscal 2023 revenue of $51.8 million, a 2.7% decrease year-over-year. However, excluding foreign currency fluctuations, revenue grew 2.3%. Active accounts fell 6.7% to 153,000, with notable declines in the Americas (7.8%) and Asia/Pacific & Europe (4.1%). Net income was $0.6 million, or $0.05 per diluted share, down from $3.3 million, or $0.25 per share a year ago. The company maintains a solid balance sheet with $17.6 million cash and no debt. Fiscal 2023 guidance remains at $200-$212 million in revenue and adjusted EBITDA of $12-$14 million.

LifeVantage Corporation (Nasdaq: LFVN) will announce its Q1 financial results for the period ending September 30, 2022, on November 2, 2022, after market close. The company will host a conference call for investors at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested parties can join the call via U.S. (855) 327-6837 or international (631) 891-4304. A replay will be available until November 9, 2022. Additionally, a live webcast will be accessible on their Investor Relations website, archived for 30 days.

LifeVantage Corporation (Nasdaq: LFVN) has announced a quarterly cash dividend of $0.03 per share, scheduled for payment on September 15, 2022, to stockholders on record as of September 2, 2022. This decision highlights the company's commitment to returning value to its shareholders. LifeVantage specializes in nutrigenomics and offers a range of products including dietary supplements and skin care solutions, while continuously focusing on innovation and growth in this sector.

LifeVantage Corporation (LFVN) reported its fourth-quarter and full-year results for fiscal 2022, revealing a 7.0% revenue decline to $50.9 million in Q4 and a 6.3% drop to $206.4 million for the full year. Active accounts decreased 8.2% to 156,000. The company experienced a net loss of $1.4 million ($0.11 per diluted share) in Q4, compared to a net income of $4.9 million ($0.35 per diluted share) in the previous year. Adjusted EBITDA was $1.7 million in Q4, significantly down from $6.6 million a year earlier. Fiscal 2023 guidance suggests revenue will range from $200 million to $212 million.

LifeVantage Corporation (Nasdaq: LFVN) will release its financial results for the fourth quarter and full fiscal year ending June 30, 2022, on August 23, 2022, after market close. A conference call for investors is scheduled at 2:30 PM MT (4:30 PM ET) on the same day. Investors can participate via phone or listen to a live webcast, with archived access available for 30 days. LifeVantage specializes in nutrigenomics, including dietary supplements and health products like Protandim® and Petandim®.